key: cord-0773498-hl1ntand
authors: Jia, Na; Zhang, Guifang; Sun, Xuelin; Wang, Yan; Zhao, Sai; Chi, Wenjie; Dong, Sitong; Xia, Jun; Zeng, Ping; Liu, Deping
title: Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
date: 2021-07-28
journal: J Clin Hypertens (Greenwich)
DOI: 10.1111/jch.14329
sha: 6be11f966bec390c3d3bf72d240ccbf7c5229694
doc_id: 773498
cord_uid: hl1ntand

Since the COVID‐19 pandemic, physicians concerned about the potential adverse effects of angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs). To explore the relationship between ACEIs/ARBs and the risk of mortality and other clinical outcomes in COVID‐19 patients, the authors conducted a systemic review and meta‐analysis. An electronic search was performed from inception to November 12, 2020 in PubMed, Medline, EMBASE, ClinicalTrials, TRIP, the Cochrane Library, CNKI, Wanfang, and CBM database. Risk of bias was assessed using the Risk Of Bias In Non‐randomized Studies of Interventions tool. The primary outcome was in‐hospital all‐cause mortality. Secondary outcomes included all‐cause mortality measured at 30‐day or longer term, mechanical ventilation, length of hospital stay, readmission, and cardiac adverse events. A total of 28 studies with 73 465 patients was included. Twenty‐two studies with 19 871 patients reported the incidence of all‐cause mortality. Results showed no association between using ACEIs/ARBs and risk of mortality crude odds ratio （OR） of 1.02, 95% CI 0.71–1.46, p = .90, I (2 )= 88%, adjusted OR in 6260 patients of 0.96, 95% CI 0.77–1.18, p = .68, I (2 )= 0%. While six studies with 10 030 patients reported a lower risk of mortality in ACEIs/ARBs group hazard ratio (HR) of 0.53, 95% CI 0.34–0.84, p = .007, I (2 )= 68%. Similar association (for HR) was found in hypertension subgroup. There was no significant association for the secondary outcomes. Based on the available data, we concluded that ACEIs/ARBs is not associated with the risk of in‐hospital all‐cause mortality in COVID‐19 patients, but may be associated with a decreased risk of 30‐day all‐cause mortality. Patients with hypertension may benefit from using ACEIs/ARBs.

Since the end of 2019, COVID-19 pneumonia erupted in many countries and became a pandemic, posing a great threat to human health and survival. SARS-Cov-2 can bind angiotensin converting enzyme 2 (ACE2) and allows the virus to invade cells, which may lead to activate immune response and lung injury. 1, 2 ACEIs or ARBs can potentially increase ACE2 level, concern has been raised about the safety of these medications in patients with COVID-19. Although many scientific institutions have recommended that ACEIs/ARBs therapy should not be discontinued in COVID-19 patients, 3 

This systematic review was carried out in accordance with the metaanalysis of observational studies in epidemiology and preferred reporting items for systematic reviews and meta-analyses statements. An electronic search was performed from PubMed, Medline, EMBASE, ClinicalTrials, TRIP, the Cochrane Library, Chinses National Knowledge Infrastructure (CNKI), Wanfang database and Chinese BioMedical (CBM) database. Drafts of protocol was developed and reviewed.

The protocol was registered on PROSPERO on August 4, 2020 (CRD42020202402). Trials were identified through a comprehensive systematic search from inception to June 21, 2020 in PubMed, Medline, EMBASE, ClinicalTrials, TRIP, the Cochrane Library, CNKI, Wanfang and CBM database using the strategies presented in Appendix 1.

No language restrictions were applied.

We included studies of patients with COVID-19 confirmed by polymerase chain reaction (PCR) or genetic tests; ACEIs /ARBs use data were provided. The interventional group was ACEIs or ARBs user. The comparator was no use of ACEIs or ARBs, irrespective of combined use with other medications.

Three reviewers (NJ, XS, and YW) screened the search titles and abstracts. All potentially relevant citations were requested and inspected in detail using the full text version. Articles without full texts, duplicated publications, reports lacking data, and articles not reporting any outcomes of interest were excluded from the analysis. Disagreements were resolved by discussion with assistance from a forth reviewer (PZ). 

Data from each study was extracted independently by two separate reviewers (SD and WC) using a pre-designed data extraction form.

Any disagreements were resolved by discussion with assistance from a third reviewer (SZ). We extracted all relevant characteristics of all included studies including general study characteristics, participants' information, intervention, characteristics of outcome, ACEIs/ARBsrelated risk factors with reported estimates of association and corresponding crude and adjusted estimates.

Meta-analysis was performed for quantitative synthesis. In cases where data was not eligible for meta-analysis, we narratively synthesized data. We summarized all dichotomous outcome data using odds ratios (ORs) or hazard ratios (HRs) and their 95% confidence intervals (CIs). We summarized all continuous outcome data using mean differences (MDs) and their 95% CIs. Heterogeneity in the study results included clinical heterogeneity, methodological heterogeneity, and statistical heterogeneity. When we suspected heterogeneity, we highlighted and fully discussed the reasons when this was possible. We visually inspected forest plots to investigate possible statistical heterogeneity; an I 2 estimate greater than or equal to 50% accompanied by a statistically significant chi-square statistic was interpreted as evidence of substantial levels of heterogeneity. If the number of studies more than 10, we conducted a funnel plot to test the reporting bias of one specific outcome. We synthesized data using a fixed-effects method for all analyses. We explored the source of heterogeneity and conducted a subgroup analysis if the source of heterogeneity was identified. We synthesized data using a random-effects model when we could not determine the source of heterogeneity. If heterogeneity was found and the source of heterogeneity was identified, a post-hoc subgroup analysis according to the particular factor was conducted. All analyses were performed in Review Manager 5.1 (The Cochrane Collaboration, Oxford, United Kingdom).

Two thousand seven hundred sixty two records were identified and 2654 trials were rejected after title-abstract screening. Of these, 117

full-text articles were assessed for eligibility, with 89 studies excluded Table 1 .

Risk of bias assessment was shown in Appendix 2. Three studies were assessed as having serious risk of bias, and 13 studies were found to be moderate risk of bias. Twelve studies were considered as having low risk of bias.

In patients with COVID-19, a total of 23 studies with 19,938 patients reported the incidence of all-cause mortality. Meta-analysis showed no association between using ACEIs/ARBs and risk of mortality (crude 

Three studies provided long-term mortality data, but the results could not be combined. Khan Seven studies with 4,576 patients reported the risk of ventilation and the result showed no association (crude OR of 1.29, 95% CI 0.85-1.96, p = .24, I 2 = 59%, Appendix 3, Figure 5 ). Among them five studies with 2,572 patients reported an adjusted OR for ventilation, still without association with ACEIs/ARBs use (adjusted OR = 1.07, 95% CI 0.74-1.54, p = .72, I 2 = 0%, Appendix 3, Figure 6 ). We narratively synthesized the results of duration of hospital stay, but did not show a significant difference. Only Richardson and coworker 8 reported readmission data, and again, there was not significantly different between the ACEIs group (3/168) and the ARBs group (3/245). Five studies provided the data of heart failure (HF). The HF event in Jung and coworker 9 was reported for the hypertension subgroup. Only two studies 10 If the study provided the mean age of two groups, the age was shown separately. If the study did not provide the age of two groups, only the mean age of the whole population was shown. b If the study provided the male/female number of two groups, the male/female number was shown separately. If the study did not provide the male/female number of two groups, only the male/female number of the whole population was shown. 

We preset the subgroup analysis for sex and age in the prior subgroup.

However, only few individual studies were available. Soleimani Figure 13 ).

in Figure 4 . For the ACEIs group, four studies (one study did not pro- 

Association between ACEI or ARB use alone and in-hospital all-cause mortality. Pooled risk of in-hospital all-cause mortality was shown as crude OR (A), adjusted OR (B), and HR (C). Studies were divided into ACEI subgroup and ARB subgroup. The effect size was pooled separately Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HR, hazard ratio; OR, odd ratio. Figure 4 ) compared with non-user. Three studies made head to head comparison between ACEIs and ARBs, but showed no significant association (crude OR of 1.11, 95% CI 0.75-1.64, p = .60, I 2 = 0%, Appendix 3, Figure 19 ).

Additionally, three studies 5,15,16 with serious risk of bias were excluded from the analyses of crude OR, adjusted OR for all-cause mortality, and we still did not find significant associations (crude OR of 1.13, 

The inconsistent conclusions about the use of ACEIs/ARBs call for more rigorous studies to demonstrate the effect of ACEIs/ARBs in different population. Several relevant systematic reviews and metaanalysis summarized available evidence and suggested continue use of ACEIs/ARBs based on the lack of association of the treatment on the risk of mortality or severity of outcomes. By using strict paper inclusion criteria, and adjusting for confounding effect whenever possible, our systematic review provided relatively higher quality of evidence to increase the assurance of using 

Based on the available data, we conclude that using ACEIs/ARBs is not associated with the risk of in-hospital all-cause mortality in COVID- 19 patients, but may be associated with a decreased risk of 30-day all-cause mortality. Patients with hypertension may benefit from using ACEIs/ARBs. 

There are no conflicts of interest to declare. 

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Structural basis of receptor recognition by SARS-CoV-2

Joint HFSA/ACC/AHA statement addresses concerns Re: using RAAS Antagonists in COVID-19. J. Cardiac Fail

Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers 2020

Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study

Update on association between exposure to reninangiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea

Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian Cohort study of 43,000 patients

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Association of Renin-angiotensinaldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)-Related Outcomes in Korea: a Nationwide Populationbased Cohort Study

Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry. Revista espanola de cardiologia (English ed)

Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China

Effects of angiotensin receptor blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: a Single-Center Retrospective Study

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: a Case Series Study

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Diabetes & metabolic syndrome

Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients. Current atherosclerosis reports

ACEIs/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: a Metaanalysis

A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Current hypertension reports

Outcomes of renin-angiotensinaldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis

Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: a Meta-Analysis

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a metaanalysis. Heart (British Cardiac Society)

Renin-angiotensinaldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and metaanalysis

Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Systematic Review and Meta-Analysis

Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis

Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis

Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis

Effects of ACEI and ARB on COVID-19 patients: a meta-analysis

Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis

A systematic review and metaanalysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: what is the evidence so far?

Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: a Systematic Review and Meta-analysis

Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Pharmacotherapy in COVID-19; A narrative review for emergency providers

ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust

Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States

Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV

Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study

Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: results From an Italian Cohort of 133 Hypertensives

Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients

A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19

Effects of angiotensin converting enzyme inhibitor /angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker on the outcome of hospitalization of patients with hypertension and novel coronavirus pneumonia

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis